Needham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics (ACER) today. The company’s shares closed last Monday at $2.02, close to its 52-week low of $1.87.
According to TipRanks.com, Belanger has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.8% and a 30.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acer Therapeutics with a $10.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.25 and a one-year low of $1.87. Currently, Acer Therapeutics has an average volume of 70.66K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome.
